As Merck moves forward with plans to close their Riverside facility, the company remains committed to its West Point location and other sites, writes Nathan Owens for Manufacturing Drive.
The Riverside plant, which once employed 300 people, was originally slated to cease production in 2024. Merck hasn’t disclosed why the timeline was delayed but noted it will support affected employees with transition services and severance benefits.
Despite the closure, Merck emphasized its continued commitment to the Keystone State, where it employs roughly 14,000 people and operates its largest pharmaceutical manufacturing site in West Point. That 400-acre facility is a major hub for vaccine production and research, and part of a $3 billion investment in Pennsylvania to date.
The Riverside plant, located along the Susquehanna River, has a long industrial history, including use during World War II. It also faced environmental scrutiny over groundwater contamination, but Merck completed EPA-approved remediation efforts in 2008 and has monitored the site since.
Nationwide, Merck continues to expand, recently opening a $1 billion vaccine manufacturing facility in Durham, North Carolina.
To learn more about Merck’s Pennsylvania operations and the Riverside plant closure, visit Manufacturing Drive.
